About BlueRock Therapeutics
BlueRock focuses on stem cell research to regenerate heart muscles after a heart attack, and to develop therapies for Parkinson’s disease.
Driven by a vision to liberate patients from degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicines. Founded in 2016, BlueRock and its team of preeminent scientists are pioneering cell therapies that restore critical natural functions in the body, with an initial focus on severe brain and heart conditions. BlueRock’s culture is defined by scientific transparency, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit.
Founder: Gordon Keller and Lorenz Studer
CEO: Emile Nuwaysir
CTO: Robert Deans
21 articles with BlueRock Therapeutics
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the establishment of partnerships with Bruce Blazar, M.D., Regents Professor of Pediatrics, Division of Blood and Marrow Transplantation at the University of Minnesota
BlueRock Therapeutics an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019 at 10:30 a.m. PT / 1:30 p.m. ET at the Westin St. Francis Hotel in San Francisco.
12/28/2018As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
The partnership encompasses an operations and infrastructure expansion. BlueRock will be moving into an additional 14,000 square feet within UHN in Toronto's MaRS Discovery District, co-located with the McEwen Institute.
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced the appointment of Min Wang, J.D., Ph.D., as Chief Legal and Administrative Officer.
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences
BlueRock Therapeutics President and CEO Emile Nuwaysir elected to serve as Vice Chairman of the Alliance for Regenerative Medicine
BlueRock Therapeutics, LP announced today that Dr. Emile Nuwaysir, the Company's President and Chief Executive Officer, has been elected Vice Chairman of the Alliance for Regenerative Medicine (ARM), an international organization representing the cell and gene therapies community.
BlueRock Therapeutics, LP today announced its participation in the Cell & Gene Meeting on the Mesa, to be held Oct. 3-5 in La Jolla, Calif.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Appointment strengthens the leadership team and accelerates the company's establishment of its novel Cell+Gene platform
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
BlueRock Therapeutics Establishes R&D Site in New York City and Formalizes Collaboration with Memorial Sloan Kettering Cancer Center
Company Receives $1 Million Incentive Through Economic Development Initiative of New York State and Empire State Development
BlueRock Therapeutics, which has locations in Toronto, NYC and Cambridge, Mass., rocketed to existence in December 2016 with $225M in venture funding to focus on regenerative medicine, using iPSC therapies.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
BlueRock Therapeutics Announces Appointment of Derek Hei, Ph.D. as Senior VP, Manufacturing, Quality and Regulatory
Dr. Hei brings to BlueRock over twenty years of experience developing breakthrough cell and gene therapies from research through clinical trials.
BlueRock was founded in 2016 when Versant Ventures and Bayer invested $225 million in a Series A financing.
BlueRock Therapeutics And Universal Cells Enter Collaboration And License Agreement To Generate Gene-Edited iPS Cell Lines
BlueRock Therapeutics Expands Toronto Presence With R&D And Manufacturing Hub, Appoints Key R&D Leadership